Improving patient outcomes with regenerative medicine: How the Regenerative Medicine Manufacturing Society plans to move the needle forward in cell manufacturing, standards, 3D bioprinting, artificial intelligence-enabled automation, education, and training.,STEM CELLS Translational Medicine

当前位置： X-MOL 学术 › Stem Cells Transl. Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Improving patient outcomes with regenerative medicine: How the Regenerative Medicine Manufacturing Society plans to move the needle forward in cell manufacturing, standards, 3D bioprinting, artificial intelligence-enabled automation, education, and training.
STEM CELLS Translational Medicine ( IF 5.4 ) Pub Date : 2020-03-28 , DOI: 10.1002/sctm.19-0389
Joshua Hunsberger ₁ , Carl Simon ₂ , Claudia Zylberberg ₃ , Preveen Ramamoorthy ₄ , Thomas Tubon ₅ , Ram Bedi ₆ , Kurt Gielen ₇ , Caitlin Hansen ₈ , Lynn Fischer ₉ , Jed Johnson ₁₀ , Priya Baraniak ₁₁ , Behzad Mahdavi ₁₂ , Taciana Pereira ₁₃ , Michael Hadjisavas ₁₄ , Shannon Eaker ₁₅ , Cameron Miller ₁₆

Affiliation

Regenerative Medicine Manufacturing Society, Winston-Salem, North Carolina, USA.
National Institute of Standards and Technology, Gaithersburg, Maryland, USA.
Akron Biotech, Boca Raton, Florida, USA.
HealthTell, University of Colorado School of Medicine, Aurora, Colorado, USA.
Madison College, Madison, Wisconsin, USA.
University of Washington, Seattle, Washington, USA.
Medace, Maastricht, Netherlands.
RoosterBio, Ballenger Creek, Maryland, USA.
Title21 Health Solutions, Pleasanton, California, USA.
Nanofiber Solutions, Hilliard, Ohio, USA.
OrganaBio, LLC, South Miami, Florida, USA.
Lonza Group Ltd, Basel, Switzerland.
Allevi, Philadelphia, Pennsylvania, USA.
QIAGEN, Hilden, Germany.
GE Healthcare, Marlborough, Massachusetts, USA.
Design Interactive, Orlando, Florida, USA.

The Regenerative Medicine Manufacturing Society (RMMS) is the first and only professional society dedicated toward advancing manufacturing solutions for the field of regenerative medicine. RMMS's vision is to provide greater patient access to regenerative medicine therapies through innovative manufacturing solutions. Our mission is to identify unmet needs and gaps in regenerative medicine manufacturing and catalyze the generation of new ideas and solutions by working with private and public stakeholders. We aim to accomplish our mission through outreach and education programs and securing grants for public‐private collaborations in regenerative medicine manufacturing. This perspective will cover four impact areas that the society's leadership team has identified as critical: (a) cell manufacturing and scale‐up/out, respectively, for allogeneic and autologous cell therapies, (b) standards for regenerative medicine, (c) 3D bioprinting, and (d) artificial intelligence‐enabled automation. In addition to covering these areas and ways in which the society intends to advance the field in a collaborative nature, we will also discuss education and training. Education and training is an area that is critical for communicating the current challenges, developing solutions to accelerate the commercialization of the latest technological advances, and growing the workforce in the rapidly expanding sector of regenerative medicine.

中文翻译：

通过再生医学改善患者治疗效果：再生医学制造协会计划如何在细胞制造、标准、3D 生物打印、人工智能驱动的自动化、教育和培训方面取得进展。

再生医学制造协会 (RMMS) 是第一个也是唯一一个致力于推进再生医学领域制造解决方案的专业协会。 RMMS 的愿景是通过创新的制造解决方案为患者提供更多获得再生医学疗法的机会。我们的使命是确定再生医学制造中未满足的需求和差距，并通过与私人和公共利益相关者合作来促进新想法和解决方案的产生。我们的目标是通过外展和教育计划以及为再生医学制造领域的公私合作获得拨款来完成我们的使命。这一观点将涵盖协会领导团队认为至关重要的四个影响领域：(a) 分别用于同种异体和自体细胞疗法的细胞制造和放大/缩小，(b) 再生医学标准，(c) 3D生物打印，以及（d）人工智能支持的自动化。除了涵盖这些领域以及社会打算以协作方式推进该领域的方式外，我们还将讨论教育和培训。教育和培训对于传达当前挑战、开发解决方案以加速最新技术进步的商业化以及在快速扩张的再生医学领域增加劳动力至关重要。

更新日期：2020-03-28

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11